InvestSMART

Imugene Limited (ASX: IMU) - Announcements

Current share price for IMU : $0.082 0.001 (1.20%)+

ASX company news and announcements for Imugene Limited (IMU) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Imugene Limited (IMU) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Imugene Limited (IMU), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Imugene Limited (IMU)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$40 Patent Protection in China and Korea 5 Nov 2007 2:24PM $0.180 $0.082 fallen by 54.44%
$40 Appendix 4C - quarterly 31 Oct 2007 1:26PM $0.175 $0.082 fallen by 53.14%
$40 PRRS Vaccine Trial Update 18 Oct 2007 12:38PM $0.195 $0.082 fallen by 57.95%
$40 Patent Protection Extended 12 Oct 2007 8:25AM $0.230 $0.082 fallen by 64.35%
$40 Expanded Vaccine Development Program 25 Sep 2007 12:15PM $0.240 $0.082 fallen by 65.83%
$40 Appendix 4E-Preliminary Final Report Year End 30 June 2007 30 Aug 2007 5:55PM $0.220 $0.082 fallen by 62.73%
$40 Fourth quarter activities and cashflow reports 31 Jul 2007 10:52AM $0.245 $0.082 fallen by 66.53%
$40 PRRS Vaccine Trial Commences in the US 18 Jul 2007 8:56AM $0.275 $0.082 fallen by 70.18%
$40 Strengthens patent protection 30 May 2007 11:13AM $0.275 $0.082 fallen by 70.18%
$40 Avian Influenza Poultry Vaccine Trial 21 May 2007 9:36AM $0.295 $0.082 fallen by 72.20%
$40 Commitments Test Entity - Third Quarter Report 30 Apr 2007 12:31PM $0.260 $0.082 fallen by 68.46%
$40 Avian Influenza Vaccine Update 14 Mar 2007 11:19AM $0.250 $0.082 fallen by 67.20%
$40 Half Yearly Report & Half Year Accounts 27 Feb 2007 6:34PM $0.225 $0.082 fallen by 63.56%
$40 Commitments Test Entity - Second Quarter Report 31 Jan 2007 3:37PM $0.285 $0.082 fallen by 71.23%
$40 Avian Influenza vaccine success in US Trials 29 Jan 2007 3:22PM $0.315 $0.082 fallen by 73.97%
$40 Trading Halt 29 Jan 2007 10:04AM $0.360 $0.082 fallen by 77.22%
$40 Avian influenza vaccine trial update 17 Jan 2007 11:50AM $0.290 $0.082 fallen by 71.72%
$40 Strengthens patent protection 8 Jan 2007 9:43AM $0.250 $0.082 fallen by 67.20%
$40 Avian Influenza vaccine moves to final trial stages 15 Dec 2006 10:51AM $0.225 $0.082 fallen by 63.56%
$40 Poultry product progresses in Merial development program 14 Nov 2006 1:55PM $0.185 $0.082 fallen by 55.68%
$40 Imugene offered $880000 grant for bird flu vaccine 8 Nov 2006 11:45AM $0.165 $0.082 fallen by 50.30%
$40 Commitments Test Entity - First Quarter Report 31 Oct 2006 2:21PM $0.140 $0.082 fallen by 41.43%
$40 Avian influenza vaccine efficacy trials 30 Oct 2006 11:52AM $0.140 $0.082 fallen by 41.43%
$40 Poultry Productivity Enhancer Passes Further Safety Trials 20 Oct 2006 11:36AM $0.125 $0.082 fallen by 34.40%
$40 Preliminary Final Report 13 Sep 2006 3:43PM $0.110 $0.082 fallen by 25.45%

1126 - 1150 of 1186 results

Page 46 of 48

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.